Biocon Biologics to present at 43rd Annual JP Morgan Healthcare Conference
Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 in San Francisco, CA.
Shreehas Tambe, Chief Executive Officer and Managing Director, will present on behalf of the Company in a session, as part of the APAC Conference Track, scheduled at 11:00 AM PST / 2:00 PM EST / 12:30 AM IST.
The presentation will focus on enabling equitable access to healthcare and treatment options including highlighting the Company’s growing range of products and pipeline, and a global presence in over 120 emerging and advanced markets that’s currently serving over 5 million patients worldwide.
"The Company’s strong track record of R&D leadership has led it to be first to market for many of its biosimilars, with 10 approved products and several more on the horizon. Biocon Biologics’ pipeline is strategically aligned to the top global therapeutic areas including oncology, immunology, diabetes, bone health, and ophthalmology, creating an opportunity for the Company to help answer unmet needs across a range of opportunities," the Company stated in a release.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: “This year’s J.P. Morgan Healthcare Conference marks an exciting milestone for Biocon Biologics as we celebrate the first anniversary of integrating the acquired global biosimilars business and engage with investors, analysts, and healthcare leaders to showcase our rapidly growing biosimilars portfolio. Looking ahead, we are poised for a transformative year, marked by a series of key product launches, strategic market expansions, and further innovation in our robust pipeline."
Read also: Biocon Biologics gets Japenese nod for Psoriasis Vulgaris injection Ustekinumab BS
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company. The Company has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.